Personalized antisense oligonucleotide therapy for CHCHD10-associated ALS
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide therapy for CHCHD10-associated ALS, covering 2025-08-05 to 2025-08-05. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS [Phase 1, Phase 2]